The Brickell Biotech team is at the forefront of driving advancement in three core therapeutic areas: hyperhidrosis, cutaneous T-cell lymphoma, and psoriasis. While there are some treatments available for these dermatologic conditions, all three markets present monumental opportunities for development. The therapeutic options currently available for these conditions are limited, coming with undesired side-effects or a lack in efficacy. Brickell strives to apply our groundbreaking research to fill these treatment gaps, allowing us to provide patients with the well-tolerated, effective, and convenient treatment options they deserve. Brickell also owns early stage research assets targeting androgenic alopecia and contact dermatitis.